Cited by 1,885Diabetes Treatment and ManagementDrug Transport and Resistance MechanismsBiochemical Analysis and Sensing Techniques

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

Open access
Thomas, Charles, Gioiello, Antimo, Noriega, Lilia, Strehle, Axelle, Oury, Julien, Rizzo, Giovanni, Macchiarulo, Antonio, Yamamoto, Hiroyasu +5 more·2009·Cell Metabolism

Abstract

TGR5 is a G protein-coupled receptor expressed in brown adipose tissue and muscle, where its activation by bile acids triggers an increase in energy expenditure and attenuates diet-induced obesity. Using a combination of pharmacological and genetic gain- and loss-of-function studies in vivo, we show here that TGR5 signaling induces intestinal glucagon-like peptide-1 (GLP-1) release, leading to improved liver and pancreatic function and enhanced glucose tolerance in obese mice. In addition, we show that the induction of GLP-1 release in enteroendocrine cells by 6alpha-ethyl-23(S)-methyl-cholic acid (EMCA, INT-777), a specific TGR5 agonist, is linked to an increase of the intracellular ATP/ADP ratio and a subsequent rise in intracellular calcium mobilization. Altogether, these data show that the TGR5 signaling pathway is critical in regulating intestinal GLP-1 secretion in vivo, and suggest that pharmacological targeting of TGR5 may constitute a promising incretin-based strategy for the treatment of diabesity and associated metabolic disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2009.08.001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Bacteria-derived secondary bile acids (lithocholic acid, deoxycholic acid) can activate the G-protein coupled bile acid receptor TGR5 in L cells, promoting peripheral release of GLP-1 and PYY.

    “Bacteria-derived secondary bile acids (lithocholic acid, deoxycholic acid) can activate the G-protein coupled bile acid receptor Gpbar1 receptor (TGR5) in L cells, promoting the peripheral release of GLP-1 and PYY (Katsuma et al., 2005;Thomas et al., 2009;Ullmer et al., 2013).”

    From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2009

    The Results section ('TGR5 overexpression modulates GLP-1 secretion in vivo'; page unavailable) reports that lithocholic acid induced GLP-1 release from ileal explants with high TGR5 expression. The Discussion also identifies TGR5-mediated GLP-1 release in enteroendocrine L cells. The copy does not establish the claim's bacterial origin, deoxycholic-acid example, or PYY release (searched: bacterial secondary bile acids, deoxycholic, and PYY). (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Bile acids induce insulin secretion directly via the transmembrane bile acid receptor Takeda G protein-coupled receptor 5 on β cells and indirectly via stimulation of L-cell derived GLP-1 and subsequent insulin release.

    “Bile acids induce insulin secretion directly via the transmembrane bile acid receptor Takeda G protein–coupled receptor 5 (on β cells and indirectly via stimulation of l-cell derived GLP-1 and subsequent insulin release (110–112).”
  • TGR5 can theoretically protect against obesity and its complications via two distinct and potentially synergistic mechanisms: increased energy expenditure and improved insulin sensitivity.

    “TGR5 is therefore a new and attractive target for treating obesity, since it can theoretically protect against obesity and its complications via two distinct and potentially synergistic mechanisms: increased energy expenditure and improved insulin sensitivity 148.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]

  • Bile acids increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin.

    “Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]

  • The effect of bile acids on energy expenditure is dependent on induction of type 2 iodothyronine deiodinase and mediated by binding to TGR5.

    “Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., & Schoonjans, K.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • University of Perugia (IT)
  • Intercept Pharmaceuticals (United States) (US)
Corresponding author
  • Auwerx, Johan
  • Schoonjans, Kristina
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2009-09
Volume
10
Issue
3
Pages
167-177
ISSN
1550-4131 (ISSN-L)
OpenAlex
W2081271380
Cited by
1,885
References
43
Citations by year
2026: 143 · 2025: 100 · 2024: 153 · 2023: 112 · 2022: 135 · 2021: 141 · 2020: 148 · 2019: 113 · 2018: 124 · 2017: 126 · 2016: 106 · 2015: 108 · 2014: 87 · 2013: 91 · 2012: 69
FWCI
47.30
Type
journal article
Language
en
Open access
Locations
  • Cell Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • European Commission
  • Centre National de la Recherche Scientifique
  • Australian Research Council
  • National Institutes of Health
  • Agence Nationale de la Recherche
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Nursing › Nutrition and Dietetics › Biochemical Analysis and Sensing Techniques
Keywords
TGR5, glucose homeostasis, glucagon-like peptide-1, enteroendocrine cells, energy expenditure, diet-induced obesity, diabesity, ATP/ADP ratio, calcium mobilization, brown adipose tissue, pancreatic function, liver function, TGR5 agonists, INT-777, incretin-based therapy
MeSH terms
Adenosine Triphosphate, Animals, Bile Acids and Salts, Calcium, Cell Line, Cholic Acids, Cricetulus, Glucose, Cricetinae, Homeostasis, Humans, Insulin, Male, Mice, Inbred C57BL, Mice, Obese, Oxidative Phosphorylation, Signal Transduction, CHO Cells, Mice, Knockout, Enteroendocrine Cells, Receptors, G-Protein-Coupled, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review